Newly Emerging Candida Specie: Should Clinicians and Mycologist be Concerned?

Main Article Content

O. F. Ashcroft
A. S. Kumurya
K. Mohammed
M. U. Iduh
A. A. Yusuf
N. M. Bunza
S. U. Nataala


The emergence of C. auris as a global nosocomial pathogen associated with multidrug resistance and high mortality rates has been recently discovered. This emerging pathogen appears to be far more able to induce systemic infection and mortality than other potential multi drug resistance (MDR) yeast pathogens even though it is found to have reduced virulence factors compared to C. albicans. There are issues with regard to the identification of C. auris using both phenotypic and molecular techniques; this has raised concerns about detecting the true scale of the problem. This mini- review elucidates on the literature available on C. auris and highlights the mechanism of pathogenesis and antifungal resistance, which will give further direction to extensive research in this field.

Candida auris, emerging infection, nosocomial pathogens, antifungal susceptibility, pathogenesis.

Article Details

How to Cite
Ashcroft, O. F., Kumurya, A. S., Mohammed, K., Iduh, M. U., Yusuf, A. A., Bunza, N. M., & Nataala, S. U. (2019). Newly Emerging Candida Specie: Should Clinicians and Mycologist be Concerned?. Asian Journal of Research in Infectious Diseases, 2(4), 1-7. Retrieved from
Minireview Article


Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Science of Translational Medicine. 2012;4:165rv13.

Pfaller MA. Epidemiology of nosocomial candidiasis: The importance of molecular typing. Brazillian Journal of Infectious Diseases. 2000;4:161–7.

Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. National Review Dis Primers. 2018;4:18026.

Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. nov. a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese Hospital Microbiology Immuno-logy. 2009;53:41-44.

Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clinical Infectious Disease. 2017;64:134-140.

Clancy CJ, Nguyen MH. Emergence of Candida auris: An international call to arms. Clinical Infectious Disease. 2017;64: 141-143.

Luana Rossato, Arnaldo Lopes Colombo. Candida auris: what have we learned about its mechanisms of pathogenicity? Frontiers of Microbiology. 2018;9:3081.

Chatterjee S, Alampalli SV, Nageshan RK, Chettiar ST, Joshi S, Tatu US. Draft genome of a commonly misdiagnosed multidrug resistant pathogen Candida auris. BMC Genomics. 2015;16:686.

Sharma C, Kumar N, Meis JF, Pandey R, Chowdhary A. Draft genome sequence of a fluconazole-resistant Candida auris strain from a Candidemia patient in India. Genome Announc. 2015;3:e722–e715.
DOI: 10.1128/genomeA

Lockhart SR, Guarner J. Emerging and reemerging fungal infections. Seminars in Diagnostic Pathology. 2019; 0740-2570.

Polke M, Hube B, Jacobsen ID. Candida survival strategies. Advances in Applied Microbiology. 2015;91:139–235.

Bentz ML, Sexton DJ, Welsh RM, Litvintseva AP. Phenotypic switching in newly emerged multidrug-resistant pathogen Candida auris. Medical Mycology; 2018.

Thompson DS, Carlisle PL, Kadosh D. Coevolution of morphology and virulence in Candida species. Eukaryot Cell. 2011; 10:1173–82.

Sherry L, Ramage G, Kean R, Borman A, Johnson EM, Richardson MD, et al. Biofilm-forming capability of highly virulent, multidrug-resistant Candida auris. Emerging Infectious Disease. 2017;23: 328–331.

Munoz JF, Gade L, Chow NA, Loparev VN, Juieng P, Farrer RA, et al. Genomic basis of multidrug-resistance, mating, and virulence in Candida auris and related emerging species. Nat Commun. 2018;9: 5346.

Lee WG, Shin JH, Uh Y, Kang MG, Kim SH, Park KH, et al. First three reported cases of Nosocomial fungemia caused by Candida auris. Journal of Clinical Micro-biology. 2011;49:3139–3142.

Chowdhary A, Anil Kumar V, Sharma C, Prakash A, Agarwal K, Babu R, et al. Multidrug-resistant endemic clonal strain of Candida auris in India. European Journal of Clinical Microbiology Infectious Disease. 2014;33:919–926.

Borman AM, Szekely A, Johnson EM. Comparative pathogenicity of United Kingdom isolates of the emerging pathogen Candida auris and Other Key Pathogenic Candida Species. mSphere. 2016;1:e189–e116.

Wang X, Bing J, Zheng Q, Zhang F, Liu J, Yue H, et al. The first isolate of Candida auris in China: clinical and biological aspects. Emerging Microbes & Infections. 2018;7:93.

Borman AM, Szekely A, Johnson EM. Comparative pathogenicity of United Kingdom isolates of the emerging pathogen Candida auris and other key pathogenic Candida Species. mSphere. 2016;1:e189–e116.

Ben-Ami R, Berman J, Novikov A, Bash E, Shachor-Meyouhas Y, Zakin S, et al. Multidrug-resistant Candida haemulonii and C. auris, Tel Aviv, Israel. Emerging Infectious Diseases. 2017;23:195–203.

Welsh RM, Bentz ML, Shams A, Houston H, Lyons A, Rose LJ, et al. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface. Journal of Clinical Microbiology. 2017;55:2996–3005.

Rapala-Kozik M, Bochenska O, Zajac D, Karkowska Kuleta J, Gogol M, Zawrotniak M, et al. Extracellular proteinases of Candida species pathogenic yeasts. Molecular Oral Microbiology. 2018;33:113–24.

Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiology of Molecular Biology Review. 2003;67:400–28.

Kumar D, Banerjee T, Pratap CB, Tilak R. Itraconazole-resistant Candida auris with phospholipase, proteinase and hemolysin activity from a case of vulvovaginitis. Journal of infectious in developing countries. 2015;9:435–437.

Larkin E, Hager C, Chandra J, Mukherjee PK, Retuerto M, Salem I, et al. The emerging pathogen Candida auris: Growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation∗. Antimicrobial Agents Chemotherapy. 2017; 61.
DOI: 10.1128/aac.02396-16

Tsang CS, Chu FC, Leung WK, Jin LJ, Samaranayake LP, Siu SC. Phos-pholipase, proteinase and haemolytic activities of Candida albicans isolated from oral cavities of patients with type 2 diabetes mellitus. Journal of Medical Microbiology. 2007;56(Pt 10):1393– 1398.

Furlaneto MC, Go´es HP, Perini HF, dos Santos RC, Furlaneto-Maia L. How much do we know about hemolytic capability of pathogenic Candida species? Folia Microbiol (Praha). 2018;63:405–12.

Rossoni RD, Barbosa JO, Vilela SFG, Jorge AOC, Junqueira JC. Comparison of the hemolytic activity between C. albicans and non-albicans Candida species. Braz Oral Res. 2013;27:484–9.

Luo G, Samaranayake LP, Yau JY. Candida species exhibit differential in vitro hemolytic activities. Journal of Clinical Microbiology. 2001;39:2971–4.

Seneviratne C, Wong S, Yuen K, Meurman J, Pa¨rna¨nen P, Vaara M, et al. Antifungal susceptibility and virulence attributes of bloodstream isolates of Candida from Hong Kong and Finland. Mycopathologia. 2011;172:389–95.

Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A, et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrobial Resist Infection Control. 2016;5:35.

Piedrahita CT, Cadnum JL, Jencson AL, Shaikh AA, Ghannoum MA, Donskey CJ. Environmental surfaces in healthcare facilities are a potential source for transmission of Candida auris and other Candida species. Infection Control and Hospital Epidemiology. 2017;38:1107–9.

Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, et al. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus-United States, May 2013-August 2016. American Journal of Transplantation. 2017;17:296–299.

Heath CH, Dyer JR, Pang S, Coombs GW, Gardam DJ. Candida auris sternal osteomyelitis in a man from Kenya visiting Australia, Emerging Infectious Disease. 2019;25:192–4.

Rutala WA, Kanamori H, Gergen MF, Sickbert-Bennett EE, Weber DJ. Susceptibility of Candida auris and Candida albicans to 21 germicides used in healthcare facilities. Infection Control Hospital Epidemiology. 2019;40:380–2.

Abdolrasouli A, Armstrong-James D, Ryan L, Schelenz S. In vitro efficacy of disinfectants utilized for skin decolonization and environmental decontamination during a hospital outbreak with Candida auris. Mycoses. 2017;60:758–63.

Cadnum JL, Shaikh AA, Piedrahita CT, Sankar T, Jencson AL, Larkin EL, et al. Effectiveness of disinfectants against Candida auris and other Candida species. Infection Control Hospital Epidemiology. 2017;38:1240–3.

Fanning S, Mitchell AP. Fungal Biofilms. PLoS Pathogens. 2012;8:e1002585.

Kean R, Delaney C, Sherry L, Borman A, Johnson EM, Richardson MD, et al. Transcriptome assembly and profiling of Candida auris reveals novel insights into biofilm-mediated resistance. mSphere 2018;3:e334–e318.

Sherry L, Ramage G, Kean R, Borman A, Johnson EM, Richardson MD, et al. Biofilm-forming capability of highly virulent, multidrug-resistant Candida auris. Emerging Infectious Disease. 2017;23: 328–331.

Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL. Candida biofilms: An update. Eukaryot Cell. 2005;4:633–8.

Fakhim H, Vaezi A, Dannaoui E, Chowdhary A, Nasiry D, Faeli L, et al. Comparative virulence of Candida auris with Candida haemulonii, Candida glabrata and Candida albicans in a Murine model. Mycoses. 2018;61:377–382.

Lockhart SR, Berkow EL, Chow N, Welsh RM. Candida auris for the clinical microbiology laboratory: Not your grandfather’s Candida species. Clinical Microbiology Newsletter. 2017;39(13):99-103.